Home›Stock Screener›Natco Pharma

Natco Pharma Share Price Today | Stock Price & Natco Pharma Share Screener

NATCOPHARM Pharmaceuticals & Biotechnology
Live Share Price NSE
₹820.60
▼ -2.30 (-0.28%)
2026-11-18 00:00:00
Live Share Price BSE
₹820.40
▼ -4.45 (-0.54%)
2026-11-18 00:00:00

As of November 18, 2026, the live Natco Pharma share price (NSE: NATCOPHARM) is ₹820.60 on NSE and ₹820.40 on BSE, down 0.28% from the previous close, with shares trading between ₹818.10 and ₹832.85 in today's trading session, and a 52-week range of ₹781.60–₹1,206.00. Track NATCOPHARM company valuation to gauge the company's total market size. Use the Natco Pharma stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Natco Pharma opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.

Key Statistics and Valuation Ratios

Over the trailing twelve months the company reported revenue of ₹1,019 and net income of ₹203, with EBITDA of ₹310, an operating margin of 27.0% and a profit margin of 19.9%.

Natco Pharma Market Cap ₹15,898.40 Cr.
NATCOPHARM P/E Ratio (TTM) 19.20
Natco Pharma P/B Ratio 1.44
EPS (TTM) ₹79.20
Dividend Yield 0.34%
Debt to Equity 0.06
NATCOPHARM 52 Week High ₹1206.00
Natco Pharma 52 Week Low ₹781.60
Operating Margin 27.00%
Profit Margin 19.92%
NATCOPHARM Revenue (TTM) ₹1,019.00
EBITDA ₹310.00
Net Income ₹203.00
Total Assets ₹11,074.00
Total Equity ₹9,221.00

Natco Pharma Share Price Chart

Track the current stock price of Natco Pharma with an interactive chart. Analyse NATCOPHARM share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Natco Pharma stock quote in one place.

The quote of ₹820.60 sits between the 52-week low of ₹781.60 and the 52-week high of ₹1,206.00, and the latest session moved -0.28% from the previous close.

Natco Pharma Company Profile - Fundamental Screener

Screen Natco Pharma company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for NATCOPHARM shares across the equity market and its stock price history, plus the wider market trend.

The company is classified under the Healthcare sector and the Pharmaceuticals & Biotechnology industry, with V C Nannapaneni listed as chairperson or CEO, and it trades under ISIN INE987B01026.

Business Overview

Natco Pharma Limited is a vertically integrated pharmaceutical company specializing in the development, manufacturing, and marketing of Finished Dosage Formulations and Active Pharmaceutical Ingredients. The company focuses on niche therapeutic areas and complex products, selling in over 40 countries. Natco operates in the Pharmaceuticals and Agro chemicals segments, with nine...more

Company Details

Classification

Sector Healthcare
Industry Pharmaceuticals & Biotechnology
Sub-Sector Pharmaceuticals & Biotechnology
Segment E

Identifiers and Leadership

Chairperson/CEO V C Nannapaneni
ISIN INE987B01026

Natco Pharma Balance Sheet Screener

Screen NATCOPHARM balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.

For 2026, total assets were ₹11,074, up from ₹8,631 in 2025.

Latest statistics put total assets at ₹11,074 and shareholder funds at ₹9,221, with a leverage ratio of 0.06.

Item 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017

Assets

Total Assets 11,074 8,631 6,906 5,657 5,109 4,792 4,588 4,303 3,715 2,318
Current Assets 0 0 0 0 0 0 0 0 0 0
Fixed Assets 2,803 2,698 2,491 2,427 2,312 2,023 1,584 1,227 1,019 833

Liabilities

Total Liabilities 0 0 0 0 0 0 0 0 0 0
Current Liabilities 172 75 80 101 135 143 118 83 47 38
Non-Current Liabilities 0 0 0 0 0 0 0 0 0 0

Shareholders' Equity

Total Equity 9,221 7,612 5,853 4,874 4,264 4,123 3,785 3,491 3,076 1,653
Share Capital 36 36 36 37 37 37 36 37 37 35
Reserves & Surplus 9,185 7,571 5,817 4,837 4,227 4,085 3,737 3,453 3,035 1,614

Natco Pharma Income Statement Screener - Profit & Revenue Analysis

Screen Natco Pharma income statement and profit fundamentals. Analyze NATCOPHARM quarterly results. Natco Pharma reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.

For 2026-Sept, revenue was ₹1,019 and net profit was ₹203, equal to earnings per unit of ₹11.31, at an operating margin of 27%.

In that period expenses were ₹709, interest cost ₹18 and tax ₹41. The next period listed, 2026-Jun, shows revenue of ₹794 and net profit of ₹207.

Item 2026-Sept 2026-Jun 2026-Mar 2025-Dec 2025-Sept 2025-Jun 2025-Mar 2024-Dec 2024-Sept 2024-Jun 2024-Mar 2023-Dec 2023-Sept 2023-Jun 2023-Mar

Revenue and Expenses

Revenue 1,019 794 817 705 1,463 1,391 1,287 651 1,435 1,411 1,110 796 1,061 1,160 927
Expenses 709 549 612 489 784 758 673 436 567 558 571 491 573 613 559

Operating Costs and Margins

EBITDA 310 246 205 217 679 633 614 215 868 853 539 305 487 548 368
Operating Profit % 27.00% 25.00% 17.00% 25.00% 42.00% 43.00% 45.00% 8.00% 59.00% 59.00% 47.00% 35.00% 44.00% 46.00% 38.00%
Depreciation 49 47 50 46 52 58 98 47 46 44 56 44 44 44 41
Interest 18 13 11 10 13 3 10 4 4 5 6 5 4 4 3

Profit and Earnings

Profit Before Tax 243 186 144 161 614 572 506 164 818 804 478 256 440 500 324
Tax 41 -21 -125 10 96 92 100 31 142 135 91 44 71 80 49
Net Profit 203 207 269 151 518 480 406 132 677 669 386 213 369 420 276
EPS 11.31 11.53 14.96 8.46 28.94 26.84 22.70 7.43 37.81 37.32 21.56 11.88 20.60 23.26 15.11

Natco Pharma Cash Flow Screener - Liquidity Fundamentals

Screen NATCOPHARM cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.

In 2026-March, operating activities generated ₹1,768, and net cash flow was an inflow of ₹79.

Over the same period, investing activities used ₹1,987 and financing activities provided ₹298.

Item 2026-March 2025-March 2024-March 2023-March 2022-March 2021-March 2020-March 2019-March 2018-March 2017-March

Cash from Operations and Investing

Operating Activities 1,768 1,697 1,212 849 47 299 417 669 464 346
Investing Activities -1,987 -1,437 -1,026 -465 4 -107 -175 -611 -1,116 -299

Financing and Net Cash

Financing Activities 298 -211 -247 -363 35 -186 -251 -51 651 -48
Net Cash Flow 79 50 -62 21 85 6 -9 7 -2 -1

Natco Pharma Shareholding Pattern Screener

See Natco Pharma shareholding pattern with promoter, FII, and DII holdings. Check Natco Pharma promoter holding and ownership changes for NATCOPHARM on TickJournal, and see how institutional stock price moves affect the market.

In 2026-Mar, promoters held 49.42%, foreign institutions 17.37%, domestic institutions 5.46% and the public 23.34%, spread across 410,970 shareholders.

The shareholder count was 410,970 in 2026-Mar, compared with 403,166 in 2026-Jun.

Item 2026-Mar 2026-Jun 2026-Sept 2026-Oct 2025-Mar 2025-Jun 2025-Sept 2025-Dec

Promoter Holding

Promoter Holding 49.42% 49.42% 49.39% 46.22% 49.56% 49.56% 49.48% 49.48%

Institutional Investors

FII Holding 17.37% 16.99% 16.00% 15.36% 17.49% 15.51% 14.09% 15.16%
DII Holding 5.46% 5.62% 6.16% 10.82% 5.65% 5.82% 5.87% 5.39%

Government, Public and Others

Govt Holding 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Public Holding 23.34% 23.41% 23.85% 22.78% 23.68% 25.22% 25.84% 25.38%
Other Holding 4.41% 4.56% 4.60% 4.82% 3.61% 3.89% 4.72% 4.58%
Shareholder Count 410,970 403,166 404,135 404,384 405,222 429,434 419,699 424,167

Dividend Yield Screener - Share Price & Share Analysis

Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Natco Pharma. Natco Pharma dividend yield can be compared with peers and other stocks in the market.

The latest dividend recorded was ₹5.00 per unit for 2026-March, a yield of 0.62%, compared with ₹6.00 for 2025-March.

Dividends are listed for 10 periods, with the three most recent payouts at ₹5.00, ₹6.00 and ₹9.50 per unit.

Period Dividend Per Share Dividend Yield
2026-March ₹5.00 0.62%
2025-March ₹6.00 0.62%
2024-March ₹9.50 1.20%
2023-March ₹5.50 0.58%
2022-March ₹4.50 0.81%
2021-March ₹5.25 0.70%
2020-March ₹6.75 0.82%
2019-March ₹6.25 1.25%
2018-March ₹8.25 1.45%
2017-March ₹6.75 0.90%

Natco Pharma Stock Index Membership - Nifty & Sensex

See which indices include Natco Pharma stock. Check NATCOPHARM index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.

The company is listed in 24 indices, including BSE 1000.

Among the benchmarks tracked are BSE 1000, BSE INDEX BSE HC, BSE INDEX BSE500, BSE INDEX MSL400.

Complete Index List

BSE 1000
BSE INDEX BSE HC
BSE INDEX BSE500
BSE INDEX MSL400
BSE INDEX SML250
BSE INDEX SMLCAP
BSE INDEX SMLSEL
NIFTY 500
NIFTY MIDSMALLCAP400 MOMENTUM QUALITY 100
NIFTY MIDSML 400
NIFTY MIDSML HLTH
NIFTY MULTI MFG
NIFTY PHARMA
NIFTY SMALLCAP250 MOMENTUM QUALITY 100
NIFTY SMLCAP 100
NIFTY SMLCAP 250
NIFTY SMLCAP 50
NIFTY TOTAL MKT
NIFTY500 EQUAL WEIGHT
NIFTY500 LARGEMIDSMALL EQUAL CAP WEIGHTED
NIFTY500 MOMENTUM 50
NIFTY500 MULTICAP
NIFTY500 MULTICAP MOMENTUM QUALITY 50
NIFTY500 SHARIAH

Natco Pharma Market Events Screener - Corporate Actions

Get Natco Pharma corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Natco Pharma stock events that may affect NATCOPHARM share price, along with derivatives, futures and options activity and sector gainers.

15 corporate actions are listed, the most recent entry being Dividend dated November 19, 2026, with a record date of November 19, 2026.

It is followed by Quarterly Result Announcement dated November 13, 2026 and Rights dated October 1, 2026.

Announcement Date Record Date Event Type Information Price Impact
2026-11-19 2026-11-19 Dividend ₹ 1.25 /share 0.20%
2026-11-13 2026-11-13 Quarterly Result Announcement NA 1.99%
2026-10-01 2026-10-01 Rights 2:21 -1.72%
2026-09-30 2026-09-30 Annual General Meeting NA 0.57%
2026-08-20 2026-08-20 Dividend ₹ 1.50 /share -6.81%
2026-08-14 2026-08-14 Quarterly Result Announcement NA 3.72%
2026-05-29 2026-05-29 Quarterly Result Announcement NA -1.94%
2026-02-18 2026-02-18 Dividend ₹ 1.50 /share 3.99%
2026-02-12 2026-02-12 Quarterly Result Announcement NA 4.49%
2025-11-20 2025-11-20 Dividend ₹ 1.50 /share 0.48%
2025-11-14 2025-11-14 Quarterly Result Announcement NA 3.21%
2025-09-25 2025-09-25 Annual General Meeting NA -0.12%
2025-08-19 2025-08-19 Dividend ₹ 2.00 /share -2.82%
2025-08-12 2025-08-12 Quarterly Result Announcement NA -3.36%
2025-05-28 2025-05-28 Quarterly Result Announcement NA 8.53%

Natco Pharma Competitors Screener - Peer Stocks Comparison

Screen NATCOPHARM competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.

The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.

Company Market Cap P/E Ratio Revenue YoY Growth Net Profit RSI
Sun Pharmaceutical 451,075 41.10 61,674 12.69% 11,565 63.60
Divis Laboratories 303,749 90.70 11,067 13.95% 2,568 78.53
Torrent Pharmaceuticals 177,632 84.50 13,886 20.34% 2,138 47.27
Laurus Labs 130,972 98.10 6,868 22.01% 890 69.60
Zydus Life Science 118,693 27.60 27,658 17.64% 5,026 52.34
Dr Reddys Laboratories 115,186 41.70 35,059 3.90% 4,158 70.24
Cipla 112,438 39.40 29,045 2.24% 3,870 54.92
Mankind Pharma 109,044 48.40 14,636 14.85% 1,938 65.43
Aurobindo Pharma 104,903 26.40 34,145 5.56% 3,503 66.06
Lupin 90,557 17.30 29,039 26.75% 5,356 44.92

Natco Pharma Company Announcements - News & Reports Screener

Screen NATCOPHARM latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.

20 recent announcements are listed, the latest dated November 17, 2026.

The next most recent announcements are dated November 16, 2026 and November 16, 2026.

Date Update Actions
2026-11-17 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-11-16 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome -
2026-11-16 Announcement under Regulation 30 (LODR)-Investor Presentation -
2026-11-16 Unaudited Financial Results For The Quarter And Half Year Ended 30Th September 2026 -
2026-11-16 Record Date For The Purpose Of 2Nd Interim Dividend For The FY 2026-27 -
2026-11-16 Board Meeting Outcome for Outcome Of Board Meeting -
2026-11-09 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation -
2026-11-04 Revised Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011. -
2026-10-30 Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011 -
2026-10-29 Board Meeting Intimation for Considering Un-Audited Financial Results For The Quarter Ended 30Th September 2026 And Declaration Of Second Interim Dividend If Any -
2026-10-29 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-10-23 Announcement under Regulation 30 (LODR)-Allotment -
2026-10-22 Closure of Trading Window -
2026-10-22 Intimation Of Closure Of The Issue Period Of The Rights Issue Of NATCO Pharma Limited (The Company) -
2026-10-19 Announcement under Regulation 30 (LODR)-Press Release / Media Release -
2026-10-16 Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 -
2026-10-13 Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011. -
2026-10-07 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-09-30 Shareholder Meeting / Postal Ballot-Scrutinizers Report -
2026-09-30 Closure of Trading Window -

Frequently Asked Questions

How is the company valued right now?

The current quote is ₹820.60, within a 52-week range of ₹781.60 to ₹1,206.00. The P/E ratio is 19.20 and the P/B ratio is 1.44, with earnings per unit of ₹79.20. Market capitalisation stands at ₹15,898.40 Cr and the dividend yield is 0.34%. The company operates in the Healthcare sector, in the Pharmaceuticals & Biotechnology industry, so compare these ratios with its sector peers in the table above.

About This Data

Quotes are sourced from the NSE and the BSE. Key statistics were last updated on November 18, 2026. This page covers 10 balance sheet periods, 15 income statement periods, 10 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.